ClinicalTrials.gg
CompletedNCT00750282Updated Nov 10, 2026Results posted

Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers

A Phase 2 interventional study of Florbetaben (BAY94-9172) in Alzheimer Disease and Amyloid Beta-Protein, sponsored by Lantheus Biosciences Ltd.. Completed at 23 sites in 5 countries. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Lantheus Biosciences Ltd. (part of Lantheus Holdings, Inc.) · Phase 2, Interventional, and Diagnostic

Updated Nov 10, 2026Posted results revisedSponsor changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
422
Allocation
Not applicable
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 213 studies in Alzheimer Disease with a site in Germany — 26 open to participants now, 39 under way, 17 of them phase 3. Alzheimer Disease · Germany.

Enrollment
83rd of 193
422 · median 356
Started
2008
with 14 others
Phase 2
57 of 213
2 open now
Registered
35th of 213
by date

Among the 213 studies in Alzheimer Disease with a site in Germany, this one is the 83rd largest by enrollment of the 193 interventional ones that give a count, is one of 15 that started in 2008, is one of 57 in phase 2, and was the 35th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

26 of the 213 studies in Alzheimer Disease with a site in Germany are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Alzheimer Disease with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission tomography (PET). IMP binds to amyloidal beta protein accumulating in brain tissue already from early stages of Alzheimer's disease (AD). IMP is therefore a potential tracer to be used for detecting amyloid plaques. For each subject it is required to visit the study centre during the screening phase, on the PET imaging day and for 1 follow-up visit on the next day. A telephone call for safety follow-up will be performed 7 days after IMP administration. During the screening phase the subject's medical, neurological and surgical history, specific laboratory tests related to AD, MRI of the brain and certain neuro-psychiatric tests will be performed. Clinical safety measures (physical examinations, vital signs, electrocardiogram (ECG) and laboratory tests) will be performed on the PET imaging day before IMP injection and monitored during and after two PET imaging sessions. Clinical safety measures will be performed again on the follow-up visit next day. The results of PET imaging with IMP will be compared between probable AD patients and healthy volunteers (HV). The clinical diagnosis is based on international validated and accepted criteria and established after comprehensive clinical and neuro-psychiatric examinations

03

Conditions studied

  • Alzheimer Disease
  • Amyloid Beta-Protein

Keywords

  • Alzheimer Disease
  • Amyloid beta-Protein
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Each subject / Healthy volunteer (HV) who meets the following criteria will be eligible for enrollment into the study:

    • Is a man or woman and is > 55 of age, whereby females must be without (confirmed by either: age >/= 60; or history of hysterectomy, or last spontaneous bleeding at least 2 years prior to the study start)
    • Has at least 6 years of education
    • Is able to provide , understand the information provided on the purpose and conduct of the trial and to comply with study procedures
    • Possesses a general health that permits adequate compliance with all study procedures
    • The subject, or the subject and caregiver (for probable AD patients) will be compliant and have a high probability of completing the study
    • Informed consent has been signed and dated (with time) by the subject and/or the subject's caregiver (for probable AD patients)
  • Inclusion criteria for HV only:

    • Has no evidence of cognitive impairment
    • Has MRI brain scan that has been judged as "normal" (age- appropriate)
  • Inclusion criteria for patients with AD only:

    • Presents with positive assessment for dementia of Alzheimer's type
    • Does not fulfill the criteria Dementia with Lewy Bodies (DLB) or Vascular Dementia (VaD)
    • MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease
    • Has a caregiver that is willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver

Exclusion Criteria:

  • Has any to MRI examination scan
  • Is scheduled for surgery and/or another invasive procedure within the time period of up to 24 hours following IMP application
  • Is allergic to the IMP or any of its constituents and/or has a history of severe allergic reactions to drugs or allergens (e.g. patients / volunteers with allergic asthma)
  • is critically ill and/or medically unstable and whose clinical course during the observation period is unpredictable
  • Has a history of exposure to any radiation >15 milli Sieverts (mSv)/year (e.g. occupational or radiation therapy)
  • Is receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)
  • Has been previously enrolled in this study or participated in a clinical study involving an pharmaceutical product within 30 days prior to screening, and/or any radiopharmaceutical
  • Has a brain tumor or other intracranial lesion, a disturbance of cerebro-spinal fluid (CSF) circulation (e.g., normal pressure hydrocephalus) and/or a history of head trauma or brain surgery
  • Has an inflammatory or infectious central nervous system (CNS) disease, e.g. multiple sclerosis, , syphilis, or Creutzfeldt-Jacob disease
  • Has a history, physical, laboratory or imaging findings indicative of a neurological or psychiatric illness
  • Has another disease that can cause disturbance of brain function (e.g. vitamin B12 or folic acid deficiency, disturbed thyroid function)
  • Has a history of alcohol or drug abuse
  • Has history of severe persistent depression
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Florbetaben (BAY94-9172)

    Drug: Florbetaben (BAY94-9172)

Interventions

  • Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions

06

What researchers measure

Primary outcomes

  1. Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth

    Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final

    Time frame: 90 - 110 min after investigational medical product (IMP) injection

  2. Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.

    Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.

    Time frame: 90 - 110 min after IMP injection

Secondary outcomes

  1. Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment

    PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed

    Time frame: 45 - 60 min and 110 - 130 min after IMP injection

  2. Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)

    The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient. Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.

    Time frame: 45-60 min, 90-110 min, 110-130 min

  3. Standard Uptake Value Ratios for Florbetaben Signal

    The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)

    Time frame: 90-110 min post injection

07

Results

Posted Jul 16, 2014

Participant flow

There were two parts in this study, Part A and Part B. Part A was conducted in Australia, Germany, Switzerland and USA. Subjects were recruited from 17 centers. HVs were age matched to subjects with probable Alzheimer's (AD). Part B was conducted in Australia, Germany, Japan, Switzerland, and USA, subjects recruited from 22 centers.

Participant flow — Overall Study
MilestonePart A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer Patients
Started6982126148
Completed6981125147
Not completed0111

Outcome measures

PrimarySpecificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth

Part A: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan which was considered a match for specificity. Standard of truth was the onsite clinical diagnosis. Two Beta-Amyloid Plaque Load (BAPL) algorithms for assessing the normality/abnormality of beta-amyloid plaque load in the brain scans were used. Using algorithm A (Majority Read), a brain scan of a subject with a BAPL score of "1" (without beta-amyloid plaque load) or "2" (with minor beta-amyloid plaque load) was considered normal and a BAPL score of "3" (with significant beta-amyloid plaque load) was considered abnormal. Using algorithm B (Average), a brain scan of a subject with a BAPL score of "1" was considered normal and a brain scan with a BAPL score of "2" or "3" was considered abnormal. Algorithm B was used in Part B and in the final

Time frame:
90 - 110 min after investigational medical product (IMP) injection
Reported as:
Number · percentage of subjects
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part A Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth
percentage of subjectsAD (Sensitivity) GroupHV (Specificity) Group
Majority Read Sens/ Spec (BAPL2 = abnormal)79.49 (70.47 to 88.51)91.18 (84.38 to 97.97)
Average Sens / Spec (BAPL2 = normal)74.79 (65.69 to 83.88)96.08 (91.85 to 100.30)
PrimarySpecificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.

Part B: For the calculation of sensitivity/specificity, a patient with probable AD was expected to have a positive florbetaben PET scan, ie,abnormal scan (BAPL scores "2" or "3") which was considered a match for sensitivity. A HV was expected to have a negative florbetaben PET scan, ie,normal scan (BAPL score "1") which was considered a match for specificity. The clinical diagnosis was established by an independent consensus panel (CP) of experts in dementia. Two independent sets of PET data reads were performed. The first set was performed by a panel of three readers who received live, instructor-led training on the visual assessment procedure. The second set was performed by a panel of five separate readers who were trained on the visual assessment procedure with electronic media.

Time frame:
90 - 110 min after IMP injection
Reported as:
Number · percentage of subjects
Specificity and Sensitivity of Florbetaben PET Scans Obtained in Part B Using Two Separate Algorithms and the Onsite Clinical Diagnosis as the Standard of Truth.
percentage of subjectsAD (Sensitivity) GroupHV (Specificity) Group
Sens / Spec (average 3 readers)67.24 (58.70 to 75.78)96.61 (93.34 to 99.88)
Sens / Spec (additional read, median 5 readers)78.5 (71.0 to 85.9)89.2 (83.6 to 94.7)
SecondarySensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment

PET scans from two additional imaging windows (45-60 min and 110-130 min) were visually assessed

Time frame:
45 - 60 min and 110 - 130 min after IMP injection
Reported as:
Number · percentage of subjects
Sensitivity and Specificity for All Participants Using Two Additional Imaging Windows for the Visual Assessment
percentage of subjectsAD (Sensitivity) Group (Part A)HV (Specificity) Group (Part A)AD (Sensitivity) Group (Part B)HV (Specificity) Group (Part B)
Sensitivity & Specificity (45-60 min)73.93 (64.88 to 82.98)94.61 (90.36 to 98.85)71.55 (63.34 to 79.76)94.07 (89.81 to 96.55)
Sensitivity & Specificity (110-130 min)70.56 (60.98 to 80.15)98.01 (95.65 to 100.37)73.04 (64.93 to 81.15)96.58 (93.29 to 99.87)
SecondaryKappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)

The agreement between 3 blinded readers concerning the visual assessment of abnormality of the brain scan (based on BAPL score) was measured by the kappa coefficient. Kappa values close to 1.0 indicate a high agreement while values close to 0 indicate random agreement.

Time frame:
45-60 min, 90-110 min, 110-130 min
Reported as:
Number · Kappa coefficient
Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)
Kappa coefficientImaging Window 45-60 Min Part AImaging Window 90-110 Min Part AImaging Window 110-130 Min Part AImaging Window 45-60 Min Part BImaging Window 90-110 Min Part BImaging Window 110-130 Min Part B
Kappa Coefficient as a Measure of Agreement Between Readers Concerning the Visual Assessment of Abnormality of the Brain Scan (Based on BAPL Score)0.560.600.670.780.860.86
SecondaryStandard Uptake Value Ratios for Florbetaben Signal

The Standard Uptake Value Ratios for florbetaben signal in the frontal cortex, lateral temporal cortex, parietal cortex, anterior cingulate, posterior cingulate cortex, occipital cortex, and cerebellum (white matter) were determined as a quantitative measure of tracer uptake. The SUV is defined as the ratio of (1) the tissue radioactivity concentration c (in MBq/kg) at time point t, and (2) the injected activity (in MBq, extrapolated to the same time t) divided by the body weight (in kg). These SUV numbers from regions of interest were then used to derive SUV ratios (SUVR) using the SUV from the cerebellar cortex as reference.)

Time frame:
90-110 min post injection
Reported as:
Mean · ratio
Standard Uptake Value Ratios for Florbetaben Signal
ratioAlzheimer's (AD) Group (Part A)Healthy Volunteer (HV) Group (Part A)Alzheimer's (AD) Group (Part B)Healthy Volunteer (HV) Group (Part B)
Frontal cortex1.608 ± 0.32071.295 ± 0.11511.646 ± 0.29051.301 ± 0.1961
Lateral temporal cortex1.571 ± 0.28811.259 ± 0.10581.619 ± 0.27871.292 ± 0.1620
Parietal cortex1.528 ± 0.28961.234 ± 0.11611.602 ± 0.27051.267 ± 0.1709
Anterior cingulate1.723 ± 0.35221.397 ± 0.14251.786 ± 0.31451.434 ± 0.2387
Posterior cingulate cortex1.795 ± 0.31491.422 ± 0.15651.852 ± 0.31871.493 ± 0.2351
Occipital cortex1.495 ± 0.22031.309 ± 0.08641.560 ± 0.24601.341 ± 0.1281
Composite SUVR1.620 ± 0.291.320 ± 0.111.678 ± 0.26991.355 ± 0.1784

Adverse events

Collected over A maximum of 64 days. Up to 56 days during the screening process and 8 days from baseline to second follow-up visit.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Healthy Volunteers—1/69 (1.4%)10/69 (14.5%)
Part A Alzheimer Patients—1/81 (1.2%)3/81 (3.7%)
Part B Healthy Volunteers—2/125 (1.6%)17/125 (13.6%)
Part B Alzheimer Patients—0/147 (0%)23/147 (15.6%)
Most frequent serious events
Most frequent serious events
EventPart A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer Patients
SyncopeNervous system disorders1/690/810/1250/147
ArrhythmiaCardiac disorders0/691/811/1250/147
Chest painGeneral disorders and administration site conditions0/691/810/1250/147
Clear cell endometrial carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/690/811/1250/147
Most frequent other events
Most frequent other events
EventPart A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer Patients
HeadacheNervous system disorders4/690/812/1252/147
HaematomaVascular disorders1/691/817/1254/147
Injection site haematomaGeneral disorders and administration site conditions0/690/812/1258/147
Application site erythemaGeneral disorders and administration site conditions3/691/810/1250/147
Injection site erythemaGeneral disorders and administration site conditions1/690/811/1256/147
Injection site irritationGeneral disorders and administration site conditions0/690/814/1251/147
ErythemaSkin and subcutaneous tissue disorders2/691/810/1250/147
Injection site painGeneral disorders and administration site conditions0/690/812/1253/147

Baseline characteristics

1. dropout in Part A occurred due to pre-treatment AEs. 2. dropouts in Part B occurred due to withdrawal of consent.

Age, Categorical
Age, Categorical(Participants)Part A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer PatientsTotal
<=18 years00000
Between 18 and 65 years2319211578
>=65 years4662104132344
Age, Continuous
Age, Continuous(years)Part A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer PatientsTotal
Mean68.2 ± 6.8670.7 ± 7.8270.7 ± 6.3073.9 ± 7.3071.4 ± 7.36
Sex: Female, Male
Sex: Female, Male(Participants)Part A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer PatientsTotal
Female39365273200
Male30457374222
Region of Enrollment
Region of Enrollment(participants)Part A Healthy VolunteersPart A Alzheimer PatientsPart B Healthy VolunteersPart B Alzheimer PatientsTotal
United States83223164
Australia9611531
Germany49716372255
Switzerland3101115
Japan00292857
08

Study locations

23 sites
  • Sun City, Arizona 85351, United States
  • Stanford, California 94305, United States
  • New Haven, Connecticut 06510, United States
  • New York, New York 10016, United States
  • New York, New York 10032, United States
  • The Bronx, New York 10461, United States
  • Providence, Rhode Island 02906, United States
  • Westmead, New South Wales 2145, Australia
  • Adelaide, South Australia 5000, Australia
  • Heidelberg, Victoria 3084, Australia
  • Erlangen, Bavaria 91054, Germany
  • München, Bavaria 81377, Germany
  • München, Bavaria 81675, Germany
  • Essen, North Rhine-Westphalia 45122, Germany
  • Jülich, North Rhine-Westphalia 52425, Germany
  • Münster, North Rhine-Westphalia 48149, Germany
  • Dresden, Saxony 01307, Germany
  • Leipzig, Saxony 04103, Germany
  • Berlin, State of Berlin 13125, Germany
  • Kobe, Hyōgo 650-0017, Japan
  • Kobe, Hyōgo 650-0047, Japan
  • Bunkyo-ku, Tokyo 113-8603, Japan
  • Zurich, Canton of Zurich 8091, Switzerland
09

References and documents

Publications

  • Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O; Florbetaben Study Group. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011 May;10(5):424-35. doi: 10.1016/S1474-4422(11)70077-1. Epub 2011 Apr 8. PubMed 21481640 ↗
  • Bullich S, Roe-Vellve N, Marquie M, Landau SM, Barthel H, Villemagne VL, Sanabria A, Tartari JP, Sotolongo-Grau O, Dore V, Koglin N, Muller A, Perrotin A, Jovalekic A, De Santi S, Tarraga L, Stephens AW, Rowe CC, Sabri O, Seibyl JP, Boada M. Early detection of amyloid load using 18F-florbetaben PET. Alzheimers Res Ther. 2021 Mar 27;13(1):67. doi: 10.1186/s13195-021-00807-6. PubMed 33773598 ↗
10

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 3 years 8 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2008
First posted
Sep 10, 2008
Start
Aug 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
May 10, 2013
Results first posted
Jul 16, 2014
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Nov 10, 2026
Sites
13 sites added, 13 sites removed
Show 13 added (9 Germany, 2 Japan, 1 United States, 1 Switzerland)
  • The Bronx · The Bronx, United States
  • Erlangen · Erlangen, Germany
  • München · München, Germany
  • München · München, Germany
  • Essen · Essen, Germany
  • Jülich · Jülich, Germany
  • Münster · Münster, Germany
  • Dresden · Dresden, Germany
  • Leipzig · Leipzig, Germany
  • Berlin · Berlin, Germany
  • Kobe · Kobe, Japan
  • Kobe · Kobe, Japan
  • Zurich · Zurich, Switzerland
Show 13 removed
  • Bronx · Bronx, United States
  • Erlangen · Erlangen, Germany
  • München · München, Germany
  • München · München, Germany
  • Essen · Essen, Germany
  • Jülich · Jülich, Germany
  • Münster · Münster, Germany
  • Dresden · Dresden, Germany
  • Leipzig · Leipzig, Germany
  • Berlin · Berlin, Germany
  • Kobe · Kobe, Japan
  • Kobe · Kobe, Japan
  • Zürich · Zürich, Switzerland
Nov 10, 2026
Sponsor
Life Molecular Imaging SA→Lantheus Biosciences Ltd.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Posted results revised
    13 sites added, 13 sites removed
    Show 13 added (9 Germany, 2 Japan, 1 United States, 1 Switzerland)
    • The Bronx · The Bronx, United States
    • Erlangen · Erlangen, Germany
    • München · München, Germany
    • München · München, Germany
    • Essen · Essen, Germany
    • Jülich · Jülich, Germany
    • Münster · Münster, Germany
    • Dresden · Dresden, Germany
    • Leipzig · Leipzig, Germany
    • Berlin · Berlin, Germany
    • Kobe · Kobe, Japan
    • Kobe · Kobe, Japan
    • Zurich · Zurich, Switzerland
    Show 13 removed
    • Bronx · Bronx, United States
    • Erlangen · Erlangen, Germany
    • München · München, Germany
    • München · München, Germany
    • Essen · Essen, Germany
    • Jülich · Jülich, Germany
    • Münster · Münster, Germany
    • Dresden · Dresden, Germany
    • Leipzig · Leipzig, Germany
    • Berlin · Berlin, Germany
    • Kobe · Kobe, Japan
    • Kobe · Kobe, Japan
    • Zürich · Zürich, Switzerland
    Sponsor Life Molecular Imaging SA→Lantheus Biosciences Ltd.
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT00750282
Responsible party
Sponsor
First posted
Sep 10, 2008
Start date
Aug 2008
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Jul 16, 2014
Last update
Nov 10, 2026

Study contacts

Andrew Stephens, PhD
study director · Lantheus Germany GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florbetaben f-18

Start the discussion